Market revenue in 2024 | USD 50.8 million |
Market revenue in 2030 | USD 67.1 million |
Growth rate | 4.7% (CAGR from 2024 to 2030) |
Largest segment | Defibrillators |
Fastest growing segment | Defibrillators |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pacemakers, Defibrillators, Cardiac Resynchronization Therapy (CRT) |
Key market players worldwide | Stryker Corp, BIOTRONIK, SCHILLER, Medtronic PLC, Abbott Laboratories, Koninklijke Philips NV, ZOLL Medical Corporation, Boston Scientific Corp, LivaNova PLC, Progetti Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cardiac rhythm management devices market will help companies and investors design strategic landscapes.
Defibrillators was the largest segment with a revenue share of 42.13% in 2024. Horizon Databook has segmented the Norway cardiac rhythm management devices market based on pacemakers, defibrillators, cardiac resynchronization therapy (crt) covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing prevalence of cardiovascular diseases, including heart attacks and arrhythmias, in Norway, contributes to a higher incidence of SCAs. Factors such as an aging population, poor dietary habits, and smoking contribute to the rise in cardiovascular diseases, leading to a higher risk of cardiac arrests.
According to the Norwegian Cardiac Arrest Registry’s annual report 2021, the incidence of cardiac arrests in Norway was around 86 per 100,000 individuals per year. Around 4,639 out-of-hospital cardiac arrest cases were reported in 2021. Furthermore, a favorable healthcare coverage policy aids market growth.
This investment allows healthcare facilities in Norway to procure state-of-the-art EP devices for diagnosing and treating cardiac arrhythmias, thereby driving demand in the CRM devices market. As per the International Trade Administration, in 2022, Norway allocated 8.1% of its GDP to healthcare, ranking it among the top countries globally for healthcare expenditure.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway cardiac rhythm management devices market, including forecasts for subscribers. This country databook contains high-level insights into Norway cardiac rhythm management devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account